14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:PTLA
Delisted

Portola Pharmaceuticals Stock Predictions

$18.03
+0 (+0%)
At Close: Sep 04, 2020
Currently predicting for Wed, 8 May 2024

PTLA Predictions History

5 years ago
GoldenNugget predicted that PTLA for 2019-05-07 is going $36.99 (0.61%)

5 years ago
NameNotImportant predicted that PTLA for 2019-05-06 is going $35.59 (-2.47%)

5 years ago
GoldenNugget predicted that PTLA for 2019-05-06 is going $36.09 (-1.10%)

5 years ago
NameNotImportant predicted that PTLA for 2019-05-03 is going $34.50 (-5.45%)

5 years ago
NameNotImportant predicted that PTLA for 2019-05-02 is going $34.10 (-4.21%)

5 years ago
NameNotImportant predicted that PTLA for 2019-04-29 is going $37.84 (2.24%)

5 years ago
NameNotImportant predicted that PTLA for 2019-04-24 is going $34.12 (-4.59%)

5 years ago
NameNotImportant predicted that PTLA for 2019-04-22 is going $35.22 (4.51%)

5 years ago
JS predicted that PTLA for 2019-04-15 is going $34.79 (0.55%)

5 years ago
JS predicted that PTLA for 2019-01-02 is going $19.60 (0.41%)

Click to get the best stock tips daily for free!

About Portola Pharmaceuticals

Portola Pharmaceuticals Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral, once-daily Factor Xa inhibitor, which is in Phase III clinical trial for treating venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge; and Andexanet alfa, a recombinant... PTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT